Background-Myocardial stunning may cause prolonged left ventricular dysfunction after exercise-induced ischemia that can be attenuated by calcium antagonists in animal models. To assess their effects in humans, we performed a randomized, double-blind crossover study comparing the calcium antagonist amlodipine (10 mg once daily) versus isosorbide mononitrate (ISMN, 50 mg once daily) on postexercise stunning. Methods and Results-Twenty-four men with chronic stable angina and normal left ventricular function underwent serial quantitative exercise stress echocardiography after 3 weeks on each treatment to assess the degree of postexercise stunning with simultaneous sestamibi single-photon emission computed tomography perfusion scans at peak stress to quantify the ischemic burden. Exercise time (Pϭ1), maximum ST depression (Pϭ0.48), and sestamibi single-photon emission computed tomography scores (Pϭ0.17) were unchanged between treatments. Stunning occurred more often with ISMN than amlodipine (82% versus 48%). The global and segmental stress echocardiography parameters of stunning were attenuated in patients while taking amlodipine compared with ISMN. Shortening fractions and ejection fractions were less impaired 30 minutes after exercise in patients receiving amlodipine (3.5Ϯ1.4% versus 2.5Ϯ1.4%, Pϭ0.014, and 59.7Ϯ5.4% versus 54.5Ϯ8%, PϽ0.001); similarly, the isovolumic relaxation period was less prolonged with amlodipine (93Ϯ15.5 versus 106.3Ϯ14.9 ms, Pϭ0.018). Conclusions-Despite comparable levels of ischemia, amlodipine attenuated stunning when compared with ISMN. This beneficial effect may relate to a prevention of the calcium overload implicated in the pathogenesis of stunning.
M
yocardial stunning, or postischemic dysfunction, is the mechanical dysfunction that persists after ischemia is relieved despite the absence of irreversible damage. 1, 2 It is thought to be an important phenomenon in clinical settings of transient ischemia and reperfusion including myocardial infarction, unstable angina, and coronary artery bypass grafting. 3, 4 Stunning has been shown to occur after ischemia induced by increased myocardial oxygen demand in animals with partial coronary stenoses, 5 and several echocardiographic studies in humans have suggested that stunning occurs after treadmill exercise. 6, 7 Recently by simultaneously measuring left ventricular (LV) function and perfusion, reversible myocardial dysfunction persisting after exercise in patients with coronary artery disease has been demonstrated to be due to myocardial stunning. 8 Abnormalities of contraction may persist for up to 1 hour, whereas diastolic abnormalities may persist for several hours after a single episode of effort angina. The duration of contractile abnormalities after exercise-induced ischemia suggests that patients may suffer important LV dysfunction as the result of myocardial stunning during daily activities.
Intracellular calcium plays a key role in myocardial contraction and relaxation, and alterations in calcium homeostasis are thought to be involved in the pathogenesis of stunning. 9 -12 Animal studies have shown that the administration of calcium antagonists during ischemia and before reperfusion can attenuate myocardial stunning. [13] [14] [15] [16] [17] [18] [19] [20] To determine whether the calcium antagonist amlodipine could attenuate exerciseinduced myocardial stunning in humans, we performed a double-blind crossover study in patients with significant coronary artery disease and chronic stable angina. Quantitative stress echocardiography was used to assess postexercise LV dysfunction, and nuclear perfusion imaging was used to quantify exercise-induced ischemia. Amlodipine was compared with an equivalent anti-ischemic dose of isosorbide mononitrate (ISMN), which has no direct effect on myocar-dial function, in an attempt to match the ischemic burden on both treatments. Potential beneficial effects of amlodipine on stunning would therefore not be attributable to an anti-ischemic action because both treatments should reduce ischemia equally.
Methods

Patient Selection
We studied 24 patients with chronic stable angina, normal resting LV function as assessed by echocardiography, and significant coronary artery disease (Ն70% stenosis in 2 major epicardial vessels demonstrated on coronary arteriography Ͻ1 month before randomization). Patient demographics are shown in Table 1 . Patients were excluded if there was a history of recent myocardial infarction, unstable angina, uncontrolled hypertension, or concomitant disease that precluded treadmill exercise. Patients were also excluded if it was not possible to obtain echocardiograms of sufficient quality to perform quantitative analysis (1 patient). The study protocol was approved by the Research Ethics Committee of the University Hospital of Wales, and all patients gave full written informed consent.
Study Protocol
After initial evaluation, patients were randomly assigned, in a double-blind fashion, to receive either oral amlodipine or ISMN for 3 weeks. After a 2-week washout phase, the patient crossed over to the alternative treatment for a further 3 weeks. The amlodipine regime comprised 5 mg once daily for 7 days followed by 10 mg once daily for 2 weeks. The ISMN regime comprised 25 mg once daily for 7 days followed by 50 mg once daily for 2 weeks. With both regimens, adjustment to the higher dose was subject to adverse events and clinical discretion. During the study, all patients received metoprolol at a stable dosage of 50 mg twice daily (although discontinued before exercise testing) and aspirin 75 mg once daily. All other antianginal medication was discontinued during the study period.
Exercise-Echocardiogram Protocol
Exercise Tests
Exercise testing was performed according to the Standard Bruce Protocol with a Marquette treadmill at the end of each treatment period 4 to 8 hours after the previous dose of study medication. ␤-Blockade was withdrawn before exercise by halving and discontinuing metoprolol at 48 hours and 24 hours, respectively. Patients were advised to avoid activities that may precipitate angina for 24 hours before the test and to use prophylactic glyceryl trinitrate up until 4 hours before study. Patients were excluded if they had angina or used prophylactic glyceryl trinitrate within 4 hours before the test. Three ECG leads (II, V 2 , and V 5 ) were continuously monitored during exercise and recovery. Blood pressure (BP) reading and 12-lead ECG were performed every 3 minutes during exercise and every 2 minutes in recovery until resolution of ECG changes and a return of heart rate and BP to baseline values. Patients exercised until they experienced chest pain and continued until limited by their symptoms. Exercise was also discontinued if a drop in systolic BP of Ն10 mm Hg or significant arrhythmias occurred with exercise.
Echocardiography
Two-dimensional echocardiograms were obtained with the patient in the left lateral decubitus position with commercially obtainable equipment (Hewlett-Packard Sonos 1500, model 77025A) with a 2.5-MHz phased array transducer. All studies were performed by the same investigator (C.A.R.). To ensure reproducibility, the position of the patient on the couch was documented at baseline and used for each image acquisition and the position of the transducer on the patient's chest was marked. To minimize beat-to-beat variation, all recordings were made in gently held expiration. Studies were recorded on super VHS videotape for later off-line analysis. LV contractile function was assessed in the apical 2-chamber (AP2CH) and apical 4-chamber (AP4CH) views as described in the guidelines from the American Society of Echocardiography. 21 Pulsed wave (PW) Doppler tracings of LV diastolic inflow at the tips of the mitral valve leaflets were recorded at rest with simultaneous recording of the phonocardiogram (in the second left intercostal space). Images were recorded at rest, immediately after exercise, and then at 15-minute intervals for 4 hours after exercise.
Echocardiographic Analysis
The videotaped images were analyzed by two experienced observers (C.A.R, A.Z.L.) using an off-line PC-based digitizing program (Thoraxcenter, Erasmus University, Rotterdam, the Netherlands). 22 Three consecutive beats (excluding extrasystolic and postextrasystolic beats) were analyzed for each time point in the AP2CH and AP4CH views. Endocardial contours were traced (excluding papillary muscles) at end diastole timed as the closure of the mitral valve leaflets and at end systole defined as the point of maximal inward excursion of the endocardial contour. The centerline method was used to assess regional LV function 23, 24 in which the computer superimposes the end-diastolic and end-systolic endocardial tracings and calculates a centerline between the two. The deviation from the centerline of 100 chords around the LV circumference is calculated after correction for the end-diastolic circumference and expressed as a percentage shortening fraction (SF). Each apical view of the LV is divided into 6 segments and the SF of the chords in each segment is averaged so that a total of 12 values are obtained (6 AP4CHϩ6 AP2CH). We calculated SF for all 12 segments (SFmean), for segments with a wall motion abnormality (SFwma), and in the segments that developed the most severe wall motion abnormalities (WMAs) after exercise (SFworst). In preliminary studies we obtained a 10% variability of SF in normal regions; for this study a change in SF from baseline of Ͼ20% was taken as abnormal (ie, WMA). A persistent WMA abnormality was one defined as present 15 and or 30 minutes after exercise. LV volumes at end diastole and end systole were calculated by using the biplane disk method, and global ejection fraction (EF) (%) was derived by using the formula LV EF (%)ϭ LV end-diastolic volumeϪLV end-systolic volume LV end-diastolic volume Analysis of diastolic indexes were performed by using a digitizing tablet and tracing PW Doppler LV inflow signal (5 consecutive beats for each time point). Multiple diastolic parameters were derived including the isovolumic relaxation period (IRP), measured as the interval between aortic valve closure from the phonocardiogram and the onset of the E wave on the Doppler trace. Other indexes included E wave maximal velocity, A wave maximal velocity, E/A wave ratio, time velocity integral of the E wave, deceleration rate, and deceleration time of the E wave.
Myocardial Perfusion Scans
Single-photon emission computerized tomography (SPECT) with 99-Technetium sestamibi (sestamibi SPECT) was performed on 3 separate occasions for each patient. A baseline scan was initially performed on a separate day at rest with the patients taking no active study medication to demonstrate resting myocardial perfusion. The two peak exercise scans were performed at the end of each treatment period. On each occasion a single peripheral intravenous injection of 400 MBq sestamibi was given. For the peak stress scans sestamibi was given at peak exercise and imaging was performed 70 minutes after exercise. Tomographic imaging was performed with an Elscint SP4 gamma camera and high-resolution low-energy collimator. The data were quantified with a dedicated PC-based workstation. Two experienced observers, (P.G.A., E.J.) blinded to the clinical and echocardiographic data analyzed the SPECT images. A 4-segment model dividing the ventricle into anterior, posterior/lateral, inferior, and septal regions was used. Each segment was given a score from 0 to 3, in which 3ϭnormal perfusion, 2ϭmild perfusion defect, 1ϭmoderate perfusion defect, and 0ϭsevere perfusion defect. Peak exercise studies were compared with the rest study, and a change in a segment score of Ͼ1 was considered abnormal. Total perfusion scores were calculated by adding the sum of each segmental score.
End Points
The primary efficacy analyses were based on a comparison of the effects of amlodipine and ISMN on the echocardiographic parameters of LV dysfunction after exercise. These were SFworst, SFmean, SFwma, EF, and IRP. Secondary efficacy parameters were time from stunning to recovery, total sestamibi SPECT scores, maximum ST-segment depression, and total exercise duration. The safety of amlodipine and ISMN was assessed from adverse events and intercurrent illnesses during treatment.
Statistical Analysis
A sample size of 24 patients was calculated to have sufficient power to give an 80% chance of detecting a significant difference between treatments at the 95% confidence level. The evaluation of efficacy was based on the intent-to-treat population with a subanalysis performed on the efficacy evaluable population. The echocardiographic parameters and maximum ST-segment depression were subjected to ANOVA if data met the homogeneity of variances assumptions; Wilcoxon rank sum tests were used to analyze data that did not meet those assumptions. Recovery times for patients who showed stunning were analyzed with logistic regression. Sestamibi SPECT scores were analyzed with Wilcoxon rank sum test. Significance values were 10% for period by treatment interactions and 5% otherwise. Adverse event data were analyzed with McNemar's test.
Results
Patient demographic details are shown in Table 1 . The mean age of patients was 60.25 years (range 47 to 75). All patients had a primary diagnosis of angina (mean duration 3.54 years). Seventeen (71%) patients had 3-vessel coronary disease and 7 (29%) had 2-vessel disease. All patients except 1 were of Caucasian origin (patient 24: Asian origin). The mean weight was 85.35 kg (range 56 to 124 kg). Most patients had at least 1 concomitant condition, most commonly hypertension and hypercholesterolemia.
Primary Efficacy: Echocardiography
Postexercise stunning was defined as a new wall motion abnormality (change in SF Ͼ20% from baseline) present at 15 and/or 30 minutes after exercise in myocardial segments that had matched perfusion defects at peak stress. Overall, fewer patients exhibited stunning during amlodipine treatment than while receiving ISMN (48% versus 82%,
Pϭ0.028).
Most wall motion abnormalities were present at 15 minutes after exercise, and the majority of abnormalities had recovered by 45 minutes after exercise. Table 2 and Figures 1, 2 , and 3 demonstrate the systolic and diastolic echocardiographic parameters after exercise. The difference between treatment groups in time to recovery was not statistically significant (Pϭ0.887). Analysis of percentage change from preexercise to 15 or 30 minutes after exercise (whenever lower SFworst occurred) showed that exercise-induced changes were less with amlodipine than ISMN for all echocardiographic parameters.
Mean echocardiographic parameters at 15 and 30 minutes after exercise and the P values for analysis of preexercise to postexercise changes are summarized in Table 3 .
All echo cardiographic data met the assumption of homogeneity of variances required for using ANOVA.
There was a significant difference between treatments in favor of amlodipine at 15 and 30 minutes after exercise for SFworst (3.3Ϯ1.7% versus 2.3Ϯ1.3% and 3.5Ϯ1.5% versus 2.5Ϯ1.4%, Pϭ0.014) and SFwma (2.8Ϯ0.8% versus 2.5Ϯ0.8% and 3.0Ϯ0.7% versus 2.6Ϯ0.9%, Pϭ0.008). The differences between SFmean were also highly significant in the same direction (3.7Ϯ0.4% versus 3.1Ϯ0.5% and 3.6Ϯ0.4% versus 3.2Ϯ0.5%, Pϭ0.001), as were differences in EF after exercise (59.5Ϯ4.9% versus 53.1Ϯ7.9% and 59.7Ϯ5.4% versus 54.5Ϯ8%, Pϭ0.0001). Nonparametric analysis of IRP revealed the effect of treatment was also highly significant in favor of amlodipine (88.5Ϯ15.6 versus 106.6Ϯ18.9 ms and 93Ϯ15.5 versus 106.3Ϯ14.9 ms, Pϭ0.0018). Figure 4 demonstrates an example of the beneficial effect of amlodipine on postexercise stunning in a study patient with 3-vessel disease.
Secondary Efficacy Parameters
Perfusion Scores
The mean sestamibi scores for each segment and mean total scores at baseline and at peak stress on both treatments are shown in Table 4 . Nonparametric analysis of total MIBI Table 5 .) There was no difference between blood pressure measurements between treatments during and after exercise.
Adverse Events
Adverse events were more frequent with ISMN than with amlodipine (46% versus 15%, Pϭ0.008, McNemar's test), with the most commonly reported adverse event being headache.
Discussion
The exercise-induced ischemia produced in this study caused significant regional wall motion abnormalities, reduced Changes in SF (meanϮSD) after exercise on both treatments in a patient with 3-vessel disease. SFworst shown for a segment of the lateral wall subtended by a critically stenosed circumflex artery. Peak sestamibi SPECT scans demonstrated a moderate perfusion defect in this area of equal severity on both treatments. With amlodipine, no significant decrease in SF occurred. With ISMN, SF was significantly decreased at both 15 and 30 minutes after exercise (to 35% and 52% of preexercise levels, respectively). *PϽ0.01 (ANOVA). global LV ejection fraction, and lengthening of IRP, which was prolonged but eventually recovered and thus fulfills the criteria for stunning. These abnormalities did not occur or were significantly less marked when the patients were receiving amlodipine compared with ISMN. Broadly, this very marked attenuation in stunning could have two explanations that are not mutually exclusive. The amlodipine may have reduced the ischemia more than the nitrates, and reduced stunning was simply due to less causative ischemia, or it may have an intrinsic antistunning effect. The results of this study and the results of previous basic and animal work strongly favor the second explanation. Most importantly, exercise time was the same in the two situations, whereas the tests of the degree of ischemia both by myocardial perfusion imaging and ST-segment analysis did not show any evidence for the reduced ischemia hypothesis, and in fact there was a slight trend in the opposite direction. Furthermore, there was no evidence of beneficial changes in hemodynamics in the amlodipine group (such as reduced afterload or negative inotropic effect) that could have reduced ischemia. In our study the favorable hemodynamic and anti-ischemic effects (defined and quantified by sestamibi SPECT) of amlodipine and ISMN were matched by virtue of the crossover design.
Previous experimental work also favors the hypothesis that calcium antagonists have a direct antistunning effect, possibly because calcium overload has a pathogenetic mechanism. Calcium antagonists confer protection from stunning in isolated hearts with improved recovery of function after global ischemia and reperfusion. 13, 14 Nifedipine, diltiazem, and verapamil reduce stunning in vivo, but it is unclear whether this is due to favorable hemodynamic changes that reduce cardiac work or a direct effect on the myocyte by a reduction in intracellular calcium. 17, 18 In conscious dogs instrumented to produce chronic coronary stenoses, recovery of exerciseinduced contractile dysfunction is shortened (5 versus 30 minutes) in dogs pretreated with diltiazem, 25 although this benefit may have been due to increased subendocardial flow in the ischemic zone. Intracoronary injection of calcium antagonists (thereby avoiding systemic hemodynamic effects) during coronary angioplasty has shown a protective effect on stunning, suggesting a direct effect caused by a reduction in intracellular calcium. 26 In a recent study in humans, systolic and diastolic dysfunction after exercise was attenuated by sublingual nifedipine but not nitroglycerin administered at peak exercise, 27 and our findings are in agreement with this. This previous study, however, had several limitations. It was unblinded and did not use patients as their own controls. Furthermore, not all patients had definite coronary disease confirmed by arteriography, and there were favorable changes in BP after exercise with nifedipine that may have contributed to its beneficial effect by a reduction in cardiac work, which might have reduced ischemia and indirectly the degree of stunning. Similarly, not all patients underwent myocardial perfusion scans and therefore a significant difference in exerciseinduced ischemia between the groups may have contributed to the reduction in stunning seen with nifedipine. Our study has controlled for these factors to a much greater degree and does not have these shortcomings. Its other main difference is that it is a study of the long-term therapy of the type that would be given to such patients in real life.
This finding may have important therapeutic implications, since it is likely that stunning occurs after episodes of ischemia during everyday life, which could result in prolonged episodes of LV dysfunction. It has been postulated that repetitive stunning of the type shown by us may result in chronic LV impairment. 28 Identification of clinically available therapeutic strategies that attenuate stunning and therefore lessen the impact of ischemia on LV function represent an important step in improving the medical management of patients with coronary artery disease.
Study Limitations
There are limitations to the use of endocardial wall excursion as the sole criterion of abnormal contractile function; neither Figure 6 . Echocardiographic analysis and sestamibi SPECT images. Left, Echocardiographic analysis of AP4CH views of the left ventricle at rest (top image) and at 15 minutes after exercise with amlodipine (middle image) and ISMN (bottom image). End-systolic and end-diastolic contours are traced, and a centerline is drawn between them from which regional SF is calculated. A reversible WMA is seen in the septum after exercise with both treatments, which is more severe on ISMN than with amlodipine. Right, Horizontal shortaxis SPECT images at rest and at peak stress on each treatment demonstrating a septal perfusion defect. Severity of the WMA is more severe with ISMN than with amlodipine despite the equivalent degree of ischemia at peak stress on MIBI SPECT.
wall thickening nor transmyocardial heterogeneity is taken into account. However, it does provide a quantitative method that is repeatable and it is likely that only subtle abnormalities of regional LV function are missed. The use of a semiquantitative scoring system for myocardial perfusion scintigraphy in SPECT may be subject to error, but again it is likely that only subtle abnormalities of myocardial perfusion were missed.
In conclusion, our data demonstrate a beneficial effect of amlodipine on postexercise LV dysfunction, and is to our knowledge the first ever randomized, double-blind study to show a beneficial effect of calcium antagonists (or any other therapy) on stunning. It is very unlikely that this benefit was mediated by a mechanism directly related to its anti-ischemic or hemodynamic effects because these parameters did not change significantly, although the exact mechanism remains undetermined. 
